incretin research

Peptide Cross-Reactivity: Off-Target Binding Guide

In May 2022, the FDA approved tirzepatide, a dual-receptor peptide built intentionally to bind two targets at once—but the mechanism behind unintended cross-reactivity in single-target designs remains poorly understood, raising questions about peptide specificity that have shadowed incretin research